Does the media refer more to BVS or LUCD?

In the previous week, Lucid Diagnostics had 8 more articles in the media than Bioventus. MarketBeat recorded 12 mentions for Lucid Diagnostics and 4 mentions for Bioventus. Bioventus' average media sentiment score of 1.00 beat Lucid Diagnostics' score of 0.53 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SSII or LUCD?

In the previous week, Lucid Diagnostics had 10 more articles in the media than SS Innovations International. MarketBeat recorded 12 mentions for Lucid Diagnostics and 2 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 1.16 beat Lucid Diagnostics' score of 0.53 indicating that SS Innovations International is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CBLL or LUCD more profitable?

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Lucid Diagnostics -876.72% N/A -116.26%

Does the media refer more to CBLL or LUCD?

In the previous week, Lucid Diagnostics had 7 more articles in the media than CeriBell. MarketBeat recorded 12 mentions for Lucid Diagnostics and 5 mentions for CeriBell. CeriBell's average media sentiment score of 0.56 beat Lucid Diagnostics' score of 0.53 indicating that CeriBell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SIBN or LUCD more profitable?

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Lucid Diagnostics -876.72% N/A -116.26%

Does the media refer more to SIBN or LUCD?

In the previous week, Lucid Diagnostics had 9 more articles in the media than SiBone. MarketBeat recorded 12 mentions for Lucid Diagnostics and 3 mentions for SiBone. SiBone's average media sentiment score of 0.60 beat Lucid Diagnostics' score of 0.53 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBNX or LUCD?

In the previous week, Lucid Diagnostics had 3 more articles in the media than Beta Bionics. MarketBeat recorded 12 mentions for Lucid Diagnostics and 9 mentions for Beta Bionics. Lucid Diagnostics' average media sentiment score of 0.53 beat Beta Bionics' score of 0.22 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lucid Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lucid Diagnostics (LUCD) Competitors

$1.00 +0.04 (+4.61%)

As of 10:44 AM Eastern

Compare

LUCD vs. BVS, SSII, CBLL, SIBN, and BBNX

Should you buy Lucid Diagnostics stock or one of its competitors? MarketBeat compares Lucid Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lucid Diagnostics include Bioventus (BVS), SS Innovations International (SSII), CeriBell (CBLL), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Lucid Diagnostics compare to Bioventus?

Bioventus (NASDAQ:BVS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Bioventus presently has a consensus price target of $14.00, suggesting a potential upside of 63.74%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 316.67%. Given Lucid Diagnostics' higher possible upside, analysts plainly believe Lucid Diagnostics is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Lucid Diagnostics had 8 more articles in the media than Bioventus. MarketBeat recorded 12 mentions for Lucid Diagnostics and 4 mentions for Bioventus. Bioventus' average media sentiment score of 1.00 beat Lucid Diagnostics' score of 0.53 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bioventus has a net margin of 4.94% compared to Lucid Diagnostics' net margin of -876.72%. Bioventus' return on equity of 29.97% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Bioventus has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.26	$22.73M	$0.41	20.85
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A

Bioventus has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Bioventus beats Lucid Diagnostics on 11 of the 17 factors compared between the two stocks.

How does Lucid Diagnostics compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

SS Innovations International has higher revenue and earnings than Lucid Diagnostics. SS Innovations International is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	16.18	-$12.13M	-$0.05	N/A
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A

In the previous week, Lucid Diagnostics had 10 more articles in the media than SS Innovations International. MarketBeat recorded 12 mentions for Lucid Diagnostics and 2 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 1.16 beat Lucid Diagnostics' score of 0.53 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SS Innovations International currently has a consensus target price of $7.00, suggesting a potential upside of 103.73%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 316.67%. Given Lucid Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

SS Innovations International has a net margin of -20.69% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Lucid Diagnostics	-876.72%	N/A	-116.26%

SS Innovations International has a beta of -1.89, indicating that its share price is 289% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Summary

Lucid Diagnostics beats SS Innovations International on 10 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

CeriBell presently has a consensus price target of $22.20, indicating a potential upside of 22.81%. Lucid Diagnostics has a consensus price target of $4.19, indicating a potential upside of 316.67%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

74.0% of Lucid Diagnostics shares are owned by institutional investors. 20.1% of CeriBell shares are owned by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CeriBell has higher revenue and earnings than Lucid Diagnostics. CeriBell is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.70	-$53.41M	-$1.63	N/A
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A

CeriBell has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

In the previous week, Lucid Diagnostics had 7 more articles in the media than CeriBell. MarketBeat recorded 12 mentions for Lucid Diagnostics and 5 mentions for CeriBell. CeriBell's average media sentiment score of 0.56 beat Lucid Diagnostics' score of 0.53 indicating that CeriBell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Summary

CeriBell and Lucid Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to SiBone?

SiBone (NASDAQ:SIBN) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, Lucid Diagnostics had 9 more articles in the media than SiBone. MarketBeat recorded 12 mentions for Lucid Diagnostics and 3 mentions for SiBone. SiBone's average media sentiment score of 0.60 beat Lucid Diagnostics' score of 0.53 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.42	-$18.90M	-$0.39	N/A
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Lucid Diagnostics	-876.72%	N/A	-116.26%

SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 48.25%. Lucid Diagnostics has a consensus target price of $4.19, suggesting a potential upside of 316.67%. Given Lucid Diagnostics' higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

98.1% of SiBone shares are held by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are held by institutional investors. 3.9% of SiBone shares are held by insiders. Comparatively, 6.8% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

SiBone beats Lucid Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Beta Bionics currently has a consensus price target of $19.70, suggesting a potential upside of 39.56%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 316.67%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Lucid Diagnostics had 3 more articles in the media than Beta Bionics. MarketBeat recorded 12 mentions for Lucid Diagnostics and 9 mentions for Beta Bionics. Lucid Diagnostics' average media sentiment score of 0.53 beat Beta Bionics' score of 0.22 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lucid Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.0% of Lucid Diagnostics shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Beta Bionics has a net margin of -60.27% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Lucid Diagnostics	-876.72%	N/A	-116.26%

Lucid Diagnostics has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	6.27	-$73.20M	-$1.51	N/A
Lucid Diagnostics	$5.13M	39.75	-$58.01M	-$0.47	N/A

Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Lucid Diagnostics beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$204.08M	$7.10B	$6.49B	$12.31B
Dividend Yield	N/A	1.21%	2.67%	5.66%
P/E Ratio	-2.14	48.66	24.05	24.76
Price / Sales	39.75	83.85	542.61	168.32
Price / Cash	N/A	25.59	27.48	37.92
Price / Book	-3.24	6.95	10.69	6.90
Net Income	-$58.01M	$159.20M	$3.57B	$337.45M
7 Day Performance	4.90%	0.12%	1.56%	2.84%
1 Month Performance	1.40%	6.17%	2.49%	4.78%
1 Year Performance	-22.09%	3.22%	26.51%	33.08%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	4.4582 of 5 stars	$1.01 +4.6%	$4.19 +316.7%	-25.5%	$204.08M	$5.13M	N/A	70	Analyst Upgrade Analyst Revision
BVS Bioventus	4.4725 of 5 stars	$9.20 +2.8%	$14.00 +52.2%	N/A	$747.64M	$568.09M	22.44	1,200	Positive News Gap Up
SSII SS Innovations International	2.9454 of 5 stars	$3.56 +0.8%	$7.00 +96.6%	-5.1%	$706.46M	$42.49M	N/A	4	Positive News Gap Up
CBLL CeriBell	2.629 of 5 stars	$18.50 +2.0%	$22.20 +20.0%	+6.9%	$688.28M	$89.06M	N/A	N/A
SIBN SiBone	2.3352 of 5 stars	$15.53 +3.7%	$23.00 +48.1%	-11.5%	$663.91M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Lucid Diagnostics compare to Bioventus?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Summary

How does Lucid Diagnostics compare to CeriBell?

Summary

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. BVS, SSII, CBLL, SIBN, and BBNX

How does Lucid Diagnostics compare to Bioventus?

Do institutionals and insiders hold more shares of BVS or LUCD?

Do analysts rate BVS or LUCD?

Does the media refer more to BVS or LUCD?

Is BVS or LUCD more profitable?

Which has better earnings & valuation, BVS or LUCD?

Which has more volatility & risk, BVS or LUCD?

Summary

How does Lucid Diagnostics compare to SS Innovations International?

Which has higher valuation & earnings, SSII or LUCD?

Does the media refer more to SSII or LUCD?

Do analysts rate SSII or LUCD?

Do insiders and institutionals hold more shares of SSII or LUCD?

Is SSII or LUCD more profitable?

Which has more volatility and risk, SSII or LUCD?

Summary

How does Lucid Diagnostics compare to CeriBell?

Do analysts rate CBLL or LUCD?

Do insiders & institutionals have more ownership in CBLL or LUCD?

Which has preferable valuation & earnings, CBLL or LUCD?

Which has more volatility & risk, CBLL or LUCD?

Does the media refer more to CBLL or LUCD?

Is CBLL or LUCD more profitable?

Summary

How does Lucid Diagnostics compare to SiBone?

Which has more risk & volatility, SIBN or LUCD?

Does the media refer more to SIBN or LUCD?

Which has stronger valuation & earnings, SIBN or LUCD?

Is SIBN or LUCD more profitable?

Do analysts rate SIBN or LUCD?

Do institutionals and insiders hold more shares of SIBN or LUCD?

Summary

How does Lucid Diagnostics compare to Beta Bionics?

Do analysts recommend BBNX or LUCD?

Does the media refer more to BBNX or LUCD?

Do insiders and institutionals hold more shares of BBNX or LUCD?

Is BBNX or LUCD more profitable?

Which has higher earnings and valuation, BBNX or LUCD?

Which has more risk and volatility, BBNX or LUCD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools